ArticleFuture science OA2018
Invasive fungal infections in high-risk patients: report from TIMM-8 2017.
Article in Future science OA, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Novel model to predict risk of invasive fungal infection and fungal prophylaxis timing.Microbiology spectrum · 2025Trial
- Cassette-Based Automated Production of 2-Deoxy-2-[Molecules (Basel, Switzerland) · 2026Article
- In vitro Combinatorial Effects of 18β-Glycyrrhetinic Acid with Azole Antifungals.Infection and drug resistance · 2026Article
- Antifungal Activity of Electrochemically Etched Nanotextured Stainless Steel against Candida albicans and Fusarium oxysporum Fungal Cells.ACS omega · 2025Article
- Article
- Diagnosis of invasive fungal infections: challenges and recent developments.Journal of biomedical science · 2023Review
- INVASIVE FUNGAL INFECTIONS IN CHILDREN TREATED FOR HEMATOLOGIC MALIGNANCIES - A FIVE-YEAR SINGLE CENTER EXPERIENCE.Acta clinica Croatica · 2022Article
- Immunogenicity and protective efficacy of a pan-fungal vaccine in preclinical models of aspergillosis, candidiasis, and pneumocystosis.PNAS nexus · 2022Article
- Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors-United States, July 2016-June 2019.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Invasive and Subcutaneous Infections Caused by Filamentous Fungi: Report from a Portuguese Multicentric Surveillance Program.Microorganisms · 2022Article
- Synthesis, Characterization, and Antifungal Activity of Silver Nanoparticles Embedded in Pullulan Matrices.Materials (Basel, Switzerland) · 2021Article
- Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis.Journal of fungi (Basel, Switzerland) · 2021Article
- Ceragenin-Coated Non-Spherical Gold Nanoparticles as Novel Candidacidal Agents.Pharmaceutics · 2021Article
- Article
- A Prospective Multicenter Cohort Surveillance Study of Invasive Aspergillosis in Patients with Hematologic Malignancies in Greece: Impact of the Revised EORTC/MSGERC 2020 Criteria.Journal of fungi (Basel, Switzerland) · 2021Article
- Performance characteristics of Fungitell STAT™, a rapid (1→3)-β-D-glucan single patient sample in vitro diagnostic assay.Medical mycology · 2021Article
- Efficacy of Posaconazole Prophylaxis for Fungal Disease in Hematology Patients Treated With Chemotherapy and Transplantation: An Open-Label, Prospective, Observational Study.Frontiers in microbiology · 2020Article
- Optimized Production of the Allylamine Antifungal "Terbinafine" byInfection and drug resistance · 2020Article
- Adherence to Antifungal Guidelines in Malignant Hematology Patients: A Review of the Literature.The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians · 2019Review
- Meningitis due to non-steroidal anti-inflammatory drugs: an often-overlooked complication of a widely used medication.BMJ case reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trends in Medical Mycology (TIMM) is the biennial meeting of the Infectious Disease Group of the European Organisation for Research and Treatment of Cancer (EORTC) and the European Confederation of Medical Mycology (ECMM). It brings together clinicians and researchers from across the world to share the latest R&Ds in medical mycology. Despite advances in treatment, invasive fungal infections remain a major cause of morbidity and mortality in certain high-risk groups of patients, particularly in immunocompromised patients, including those undergoing solid organ transplantation and those with acute leukemia. The challenges for clinicians are now compounded by the rapid development of multidrug resistance. The latest data and approaches to identifying patients at high risk for invasive fungal infections, ensuring early diagnosis and achieving effective treatment, including when and how to use therapeutic drug monitoring with azoles, were shared with >1000 clinicians and researchers from around the world attending the eighth TIMM, held in Belgrade, Serbia, in October 2017 (TIMM-8 2017).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.